A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-naive and Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients

Trial Profile

A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-naive and Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Dexamethasone; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Janssen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 May 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 10 Feb 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Jun 2015 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top